Limitation of current treatment in nAMD
While current therapies have improved the management of neovascular AMD, they remain limited by narrow biological targeting, frequent treatment burden, and declining efficacy over time. At Orsight Pharma, we are pioneering a novel approach that addresses these critical gaps to offer more durable, effective, and patient-friendly solutions.
Current biologics for neovascular AMD primarily target the VEGF pathway, requiring frequent injections and often leading to diminishing efficacy over time. Orsight Pharma offers a novel small molecule therapy that addresses broader disease mechanisms to achieve sustained outcomes.
Designed for Durability, Safety, and Broader Patient Benefit
Our novel small molecule therapy targets MetAP2, offering a new mechanism beyond VEGF inhibition. It is designed for long-term durability with fewer injections, enhanced safety through low immunogenicity, and the potential to benefit a broader range of patients, including those who do not respond to current treatments.
Novel Mechanism
Targets disease pathways missed by anti-VEGF.
Long-Term Durability
Reduces injection frequency and relapse risk.
Global Accessibility
Small molecule design enables cost-effective production and broad access.
Enhanced Safety
Low immunogenicity and improved tissue penetration.
Interested in learning more about our breakthrough therapy?
Reach out to Orsight Pharma to explore partnership, investment, or collaboration opportunities.
- contact@orsight-pharma.com
- Orsight Pharma 13 Wadi El-Haj Street, Nazareth, Israel
